Paper16140331
The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.
Ko J and 4 others. J Surg Res, 2005. Cited by 33 papers, by iCite.
Cite this record
ConductScience Library. The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. Papers, record 16140331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16140331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Piperidines | Major topic |
| Quinazolines | Major topic |
| Skin | Major topic |
| Vascular Endothelial Growth Factor Receptor-2 | Major topic |
| Wound Healing | Major topic |
| Wounds and Injuries | Major topic |
| Animals | |
| Body Weight | |
| Dermatologic Surgical Procedures | |
| Female | |
| Mice | |
| Mice, Inbred BALB C | |
| Microcirculation | |
| Neovascularization, Physiologic | |
| Signal Transduction | |
| Stress, Mechanical |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 5 K23 CA85582-03 | NCI NIH HHS | United States | K23CA855820 | PubMed | NIH RePORTER |
| GM0679 | NIGMS NIH HHS | United States | K12GM000679 | PubMed and NIH | NIH RePORTER |
| K23CA085582 | NIH | NIH RePORTER |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40251464 | The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair. | Int Wound J | 2025 | https://conductscience.org/library/papers/40251464 | PubMed |
| 38611066 | Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38611066 | PubMed |
| 33746571 | Identification of key genes and pathways in scleral extracellular matrix remodeling in glaucoma: Potential therapeutic agents discovered using bioinformatics analysis. | Int J Med Sci | 2021 | https://conductscience.org/library/papers/33746571 | PubMed |
| 30087804 | VEGF Receptor-2 Activation Mediated by VEGF-E Limits Scar Tissue Formation Following Cutaneous Injury. | Adv Wound Care (New Rochelle) | 2018 | https://conductscience.org/library/papers/30087804 | PubMed |
| 28631382 | A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. | Int J Cancer | 2017 | https://conductscience.org/library/papers/28631382 | PubMed |
| 25602294 | Acute cutaneous wounds treated with human decellularised dermis show enhanced angiogenesis during healing. | PLoS One | 2015 | https://conductscience.org/library/papers/25602294 | PubMed |
| 24526268 | Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients. | Drug Saf | 2014 | https://conductscience.org/library/papers/24526268 | PubMed |
| 22850548 | Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. | Br J Cancer | 2012 | https://conductscience.org/library/papers/22850548 | PubMed |
| 22258296 | Perioperative polyphenon E- and siliphos-inhibited colorectal tumor growth and metastases without impairment of gastric or abdominal wound healing in mouse models. | Surg Endosc | 2012 | https://conductscience.org/library/papers/22258296 | PubMed |
| 20978113 | Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis. | Cancer Prev Res (Phila) | 2010 | https://conductscience.org/library/papers/20978113 | PubMed |
| 19687425 | Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. | Arch Dermatol | 2009 | https://conductscience.org/library/papers/19687425 | PubMed |
| 18427552 | Regulation of scar formation by vascular endothelial growth factor. | Lab Invest | 2008 | https://conductscience.org/library/papers/18427552 | PubMed |
| 18004538 | [Pathophysiology of wound healing and current treatment strategies in a urological context]. | Urologe A | 2007 | https://conductscience.org/library/papers/18004538 | PubMed |
| 17519900 | Mechanisms of adverse effects of anti-VEGF therapy for cancer. | Br J Cancer | 2007 | https://conductscience.org/library/papers/17519900 | PubMed |
| 16763865 | [(Side) effects of VEGF inhibition]. | Ophthalmologe | 2006 | https://conductscience.org/library/papers/16763865 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16140331
GET https://conductscience.org/api/papers/v1/16140331/authors